Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IDEAYA Biosciences (IDYA) EBITDA Margin (2020 - 2025)

IDEAYA Biosciences' EBITDA Margin history spans 6 years, with the latest figure at 763.68% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 114112.0% year-over-year to 763.68%; the TTM value through Dec 2025 reached 1032.02%, up 288550.0%, while the annual FY2025 figure was 51.32%, 386621.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 763.68% at IDEAYA Biosciences, up from 1904.8% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 4.18% in Q3 2022 and bottomed at 1904.8% in Q4 2024.
  • The 5-year median for EBITDA Margin is 363.55% (2023), against an average of 501.3%.
  • The largest annual shift saw EBITDA Margin crashed -107271bps in 2024 before it skyrocketed 114112bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 637.2% in 2021, then increased by 10bps to 573.6% in 2022, then tumbled by -45bps to 832.09% in 2023, then crashed by -129bps to 1904.8% in 2024, then skyrocketed by 60bps to 763.68% in 2025.
  • Per Business Quant, the three most recent readings for IDYA's EBITDA Margin are 763.68% (Q4 2025), 1904.8% (Q4 2024), and 832.09% (Q4 2023).